Dian Diagnostics sees revenue dip in Q1 2025

Dian Diagnostics Group (SZSE:300244) today announced its first-quarter results for 2025, revealing a revenue decline to CNY 2.365 billion, a 20.45% decrease from CNY 2.973 billion in the same period last year. Net profit attributable to shareholders was a loss of CNY -21.006 million, significantly down from a profit of CNY 23.17 million year-over-year. Excluding non-recurring items, the net loss was CNY -26.306 million, compared to a profit of CNY 23.536 million the previous year. The basic and diluted earnings per share both stood at CNY -0.0344, versus CNY 0.0371 last year. The company noted a decrease in cash flow from operations to CNY -169.217 million, an improvement from CNY -266.946 million. Dian Diagnostics attributes the revenue decrease to policies related to centralized procurement and price adjustments, but emphasized its focus on internal management improvements and sustainable development. The gross margin has increased by approximately 1%.